DK2089361T3 - Inhibitorer af natriumglucose-cotransportør 2 og fremgangsmåder til deres anvendelse - Google Patents

Inhibitorer af natriumglucose-cotransportør 2 og fremgangsmåder til deres anvendelse

Info

Publication number: DK2089361T3
Authority: DK; Denmark
Prior art keywords: transporter; inhibitors; methods; sodium glucose; glucose
Prior art date: 2006-09-29

Application number

DK07843301.8T

Other languages

English (en)

Other versions

DK2089361T5 (da

Inventor

Nicole Cathleen Goodwin

Ross Mabon

Bryce A Harrison

David S Kimball

David B Rawlins

Original Assignee

Lexicon Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-29

Filing date

2007-09-27

Publication date

2011-04-18

2007-09-27 Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc

2011-04-18 Application granted granted Critical

2011-04-18 Publication of DK2089361T3 publication Critical patent/DK2089361T3/da

2012-01-16 Publication of DK2089361T5 publication Critical patent/DK2089361T5/da

Links

WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title 1
102000003673 Symporters Human genes 0.000 title 1
108090000088 Symporters Proteins 0.000 title 1
239000008103 glucose Substances 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
229910052708 sodium Inorganic materials 0.000 title 1
239000011734 sodium Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
- C07D291/06—Six-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Crystallography & Structural Chemistry (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrane Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)
Saccharide Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK07843301.8T 2006-09-29 2007-09-27 Inhibitorer af natriumglucose-cotransportør 2 og fremgangsmåder til deres anvendelse DK2089361T5 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US84815606P	2006-09-29	2006-09-29
US90571407P	2007-03-08	2007-03-08
US94878007P	2007-07-10	2007-07-10
PCT/US2007/079654 WO2008042688A2 (en)	2006-09-29	2007-09-27	Phlorizin analogs as inhibitors of sodium glucose co-transporter 2

Publications (2)

Publication Number	Publication Date
DK2089361T3 true DK2089361T3 (da)	2011-04-18
DK2089361T5 DK2089361T5 (da)	2012-01-16

Family

ID=38947681

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK10194063.3T DK2308841T3 (da)	2006-09-29	2007-09-27	Phlorizinanaloge som SGLT2-inhibitorer
DK07843301.8T DK2089361T5 (da)	2006-09-29	2007-09-27	Inhibitorer af natriumglucose-cotransportør 2 og fremgangsmåder til deres anvendelse

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK10194063.3T DK2308841T3 (da)	2006-09-29	2007-09-27	Phlorizinanaloge som SGLT2-inhibitorer

Country Status (24)

Country	Link
US (5)	US7781577B2 (da)
EP (2)	EP2308841B1 (da)
JP (3)	JP5283625B2 (da)
KR (2)	KR101492277B1 (da)
AR (1)	AR063047A1 (da)
AT (1)	ATE496888T1 (da)
AU (1)	AU2007304971B2 (da)
BR (1)	BRPI0717156B8 (da)
CA (1)	CA2664688C (da)
DE (1)	DE602007012292D1 (da)
DK (2)	DK2308841T3 (da)
EA (1)	EA016511B1 (da)
ES (1)	ES2477216T3 (da)
FR (1)	FR19C1053I2 (da)
HU (1)	HUS1900038I1 (da)
IL (1)	IL197836A (da)
MX (1)	MX2009003305A (da)
NL (1)	NL301003I2 (da)
NO (1)	NO345139B1 (da)
NZ (1)	NZ575811A (da)
PL (2)	PL2089361T4 (da)
PT (2)	PT2089361E (da)
TW (1)	TWI499414B (da)
WO (1)	WO2008042688A2 (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI499414B (zh) *	2006-09-29	2015-09-11	Lexicon Pharmaceuticals Inc	鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ２）的抑制物與其應用方法
US7846945B2 (en) *	2007-03-08	2010-12-07	Lexicon Pharmaceuticals, Inc.	Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
ES2375800T3 (es) *	2007-07-26	2012-03-06	Lexicon Pharmaceuticals, Inc.	Métodos y compuestos útiles para la preparación de inhibidores de cotransportador 2 de sódio-glucosa.
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2010009243A1 (en)	2008-07-15	2010-01-21	Theracos, Inc.	Deuterated benzylbenzene derivatives and methods of use
TWI472521B (zh) *	2008-07-17	2015-02-11	Lexicon Pharmaceuticals Inc	（２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
NZ599945A (en)	2009-11-02	2014-05-30	Pfizer	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2011070592A2 (en)	2009-12-09	2011-06-16	Panacea Biotec Ltd.	Novel sugar derivatives
TWI562775B (en) *	2010-03-02	2016-12-21	Lexicon Pharmaceuticals Inc	Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en)	2010-06-18	2015-01-13	Sanofi	Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012025857A1 (en) *	2010-08-23	2012-03-01	Hetero Research Foundation	Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
CN102453026A (zh)	2010-10-27	2012-05-16	上海艾力斯医药科技有限公司	C-芳基葡糖苷衍生物、制备方法及其应用
IL295438B2 (en)	2011-01-05	2026-05-01	Lexicon Pharmaceuticals Inc	Compositions containing and methods for using inhibitors of sodium-glucose cotransporters 1 and 2
JP5876570B2 (ja) *	2011-06-01	2016-03-02	グリーン・クロス・コーポレイションＧｒｅｅｎＣｒｏｓｓＣｏｒｐ．	Ｓｇｌｔ２阻害剤としての新規のジフェニルメタン誘導体
EA201301354A1 (ru)	2011-06-03	2014-05-30	Бёрингер Ингельхайм Интернациональ Гмбх	Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
WO2012172566A2 (en) *	2011-06-13	2012-12-20	Panacea Biotec Ltd.	Novel sglt inhibitors
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2755722B1 (en)	2011-09-13	2017-05-24	Panacea Biotec Ltd.	Novel sglt inhibitors
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2925735B1 (en) *	2012-11-20	2019-03-13	Lexicon Pharmaceuticals, Inc.	Inhibitors of sodium glucose cotransporter 1
WO2014119787A1 (ja)	2013-02-04	2014-08-07	大正製薬株式会社	便秘症の予防又は治療薬
CN103073606B (zh) *	2013-02-05	2016-05-18	中国医药研究开发中心有限公司	5’-s-(4,4’-二甲氧基三苯甲基)-2’-脱氧肌苷的合成与制备方法
EP4245765A3 (en)	2013-04-04	2024-03-20	Boehringer Ingelheim Vetmedica GmbH	Treatment of metabolic disorders in equine animals
ES2969764T3 (es)	2013-12-17	2024-05-22	Boehringer Ingelheim Vetmedica Gmbh	Un inhibidor de SGLT-2 para usar en el tratamiento de un trastorno metabólico en animales felinos
CN115282284A (zh)	2014-01-23	2022-11-04	勃林格殷格翰动物保健有限公司	犬科动物中代谢紊乱的治疗
ES2811261T3 (es)	2014-04-01	2021-03-11	Boehringer Ingelheim Vetmedica Gmbh	Tratamiento de trastornos metabólicos en animales equinos
HUE068152T2 (hu)	2014-09-25	2024-12-28	Boehringer Ingelheim Vetmedica Gmbh	SGLT2-gátlók és dopamin agonisták kombinációs kezelése anyagcserezavarok megelõzésére lófélékben
MX389367B (es)	2015-08-27	2025-03-20	Boehringer Ingelheim Vetmedica Gmbh	Composiciones farmaceuticas liquidas que comprenden inhibidores de sglt-2.
CN109195980B (zh) *	2016-05-25	2022-05-17	苏州科睿思制药有限公司	一种钠-葡萄糖协同转运蛋白抑制剂药物的新晶型及其制备方法和用途
EA201990951A1 (ru)	2016-10-19	2019-11-29		Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
EP3712147B8 (en) *	2018-01-05	2023-04-26	Shandong Danhong Pharmaceutical Co., Ltd.	Sglts inhibitor and application thereof
WO2019166958A1 (en) *	2018-02-28	2019-09-06	Mylan Laboratories Ltd	Process for the preparation of sotagliflozin
CN111989103A (zh)	2018-04-17	2020-11-24	勃林格殷格翰国际有限公司	药物组合物、其治疗方法和用途
WO2019215633A1 (en) *	2018-05-09	2019-11-14	Janssen Pharmaceutica Nv	5,5-difluoro- and 5-fluoro-5-methyl-c-glycoside derivatives useful as dual sglt1 / sglt2 modulators
WO2020039394A1 (en)	2018-08-24	2020-02-27	Novartis Ag	New drug combinations
WO2020089025A1 (en)	2018-10-29	2020-05-07	Boehringer Ingelheim International Gmbh	Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
SG11202102440SA (en)	2018-10-29	2021-04-29	Boehringer Ingelheim Int	Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
JP7482146B2 (ja) *	2019-03-01	2024-05-13	レクシコンファーマシューティカルズインコーポレイテッド	１型真性糖尿病を有する患者の治療のためのソタグリフロジンの使用
US20220324897A1 (en) *	2019-07-05	2022-10-13	Shandong Danhong Pharmaceutical Co., Ltd.	Crystal form of sglt inhibitor and application thereof
CA3145678C (en) *	2019-07-26	2022-08-23	Medshine Discovery Inc.	Sglt2/dpp4 inhibitor and application thereof
MX2022001029A (es) *	2019-07-26	2022-05-24	Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd	Inhibidor de sglts/dpp4 y aplicación del mismo.
EP3771480A1 (en) *	2019-08-01	2021-02-03	Lexicon Pharmaceuticals, Inc.	Continuous process for preparing the crystalline form ii of sotagliflozin
CN114727624A (zh)	2019-11-28	2022-07-08	勃林格殷格翰动物保健有限公司	Sglt-2抑制剂在非人哺乳动物的停奶中的用途
KR20220143732A (ko)	2020-02-17	2022-10-25	베링거잉겔하임베트메디카게엠베하	고양이과에서 심장 질환을 예방 및/또는 치료하기 위한 sglt-2 억제제의 사용
CN111763197A (zh) *	2020-07-08	2020-10-13	青岛大学	一种新型手性吲哚类化合物的合成方法
EP4249479A4 (en) *	2020-11-19	2024-12-18	Beijing Increase Innovative Drug Co., Ltd.	GLUCOSIDE DERIVATIVE, ITS PREPARATION METHOD AND ITS APPLICATION
MX2024001184A (es)	2021-07-28	2024-02-27	Boehringer Ingelheim Vetmedica Gmbh	Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos.
MX2024001185A (es)	2021-07-28	2024-02-27	Boehringer Ingelheim Vetmedica Gmbh	Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades renales en mamiferos no humanos.
EP4376819A1 (en)	2021-07-28	2024-06-05	Boehringer Ingelheim Vetmedica GmbH	Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
EP4531810A1 (en)	2022-05-25	2025-04-09	Boehringer Ingelheim Vetmedica GmbH	Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
US20240307628A1 (en)	2023-03-06	2024-09-19	Boehringer Ingelheim Vetmedica Gmbh	Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
WO2024240632A1 (en)	2023-05-24	2024-11-28	Boehringer Ingelheim Vetmedica Gmbh	Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
KR20260019532A (ko)	2023-05-24	2026-02-10	베링거잉겔하임베트메디카게엠베하	하나 이상의 sglt-2 억제제와 텔미사르탄을 포함하는 비인간 포유류의 신장 질환 및/또는 고혈압의 병용 치료 및/또는 예방
US20250108032A1 (en)	2023-09-28	2025-04-03	Lexicon Pharmaceuticals, Inc.	Methods of treating type 1 diabetes and kidney disease
US20250114323A1 (en)	2023-10-06	2025-04-10	Lexicon Pharmaceuticals, Inc.	Methods of reducing the risk of cardiovascular events in patients with left ventricular hypertrophy
WO2025160910A1 (en) *	2024-02-01	2025-08-07	New Wish Biotechnology Wuxi Co., Ltd.	Indazole compound and pharmaceutical composition, preparation method and use thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3870699A (en) *	1973-03-06	1975-03-11	Upjohn Co	Lincomycin analogs
CN1020944C (zh)	1990-01-30	1993-05-26	阿图尔-费希尔股份公司费希尔厂	紧固件
WO1995016049A1 (en)	1993-12-08	1995-06-15	The Scripps Research Institute	Catalytic chemo-enzymatic asymmetric synthesis of carbohydrates
US6214331B1 (en) *	1995-06-06	2001-04-10	C. R. Bard, Inc.	Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
JP2885191B2 (ja)	1996-07-09	1999-04-19	日本電気株式会社	液晶プロジェクタ
JP3928197B2 (ja)	1997-01-23	2007-06-13	住友化学株式会社	アリール置換芳香族類の製造方法
US6664399B1 (en)	1999-09-02	2003-12-16	E. I. Du Pont De Nemours & Company	Triazole linked carbohydrates
US6515117B2 (en)	1999-10-12	2003-02-04	Bristol-Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en)	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
US7465712B2 (en)	2000-03-17	2008-12-16	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en)	2000-03-30	2004-01-27	Bristol-Myers Squibb Company	O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en)	2000-03-30	2003-04-29	Bristol-Myers Squibb Company	O-glucosylated benzamide SGLT2 inhibitors and method
US6653290B2 (en)	2000-10-06	2003-11-25	Bristol-Myers Squibb Company	Tumor proliferation inhibitors
AU2002223127A1 (en)	2000-11-30	2002-06-11	Kissei Pharmaceutical Co., Ltd. Intellectual Property	Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
SI1354888T1 (sl)	2000-12-28	2009-10-31	Kissei Pharmaceutical	Glukopiranoziloksipirazolni derivati in njihova uporaba v zdravilih
US6936590B2 (en)	2001-03-13	2005-08-30	Bristol Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
ES2258141T3 (es)	2001-04-11	2006-08-16	Bristol-Myers Squibb Company	Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
FR2826653B1 (fr)	2001-06-29	2005-10-14	Servier Lab	Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JPWO2003011880A1 (ja)	2001-07-31	2004-11-18	キッセイ薬品工業株式会社	グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
EP1889839B1 (en)	2001-08-08	2013-11-06	Tobira Therapeutics, Inc.	Bicyclic compound, production and use as HIV inhibitors
US20030087843A1 (en)	2001-09-05	2003-05-08	Washburn William N.	O-pyrazole glucoside SGLT2 inhibitors and method of use
WO2003022861A1 (en)	2001-09-13	2003-03-20	Bristol-Myers Squibb Company	Process for the preparation of rebeccamycin and analogs thereof
FR2831169B1 (fr)	2001-10-22	2003-12-12	Servier Lab	Nouveaux derives d'hydroxyalkyle indolocarbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2002361656A1 (en)	2001-12-14	2003-06-30	Purdue Research Foundation	Enantiopure 4-deoxypentenosides, dihydropyrans and tetrahydropyrans and syntheses thereof
US6927294B1 (en) *	2002-03-08	2005-08-09	University Of Southern California	Nitrogen-containing heterocycles
DE10213228A1 (de)	2002-03-25	2003-10-16	Bayer Ag	Cyclopenten-Derivate
US6562791B1 (en)	2002-03-29	2003-05-13	Council Of Scientific And Industrial Research	Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
AU2003254903B9 (en) *	2002-08-09	2008-08-21	Taisho Pharmaceutical Co., Ltd.	Method for selective preparation of aryl 5-thio-beta-D-aldohexopyranosides
AU2002951247A0 (en)	2002-09-06	2002-09-19	Alchemia Limited	Compounds that interact with kinases
FR2845995A1 (fr)	2002-10-16	2004-04-23	Servier Lab	Nouveaux derives de pyrrolo[3,4-c]carbazole et de pyrido[2,3-b]pyrrolo[3,4-e]indole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2845996A1 (fr)	2002-10-16	2004-04-23	Servier Lab	Nouveaux derives de[3,4-a:3,4-c]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20060035844A1 (en)	2002-12-04	2006-02-16	Fumiaki Ito	Preventive or remedy for diseases caused by hyperglycemia
DE10258008B4 (de)	2002-12-12	2006-02-02	Sanofi-Aventis Deutschland Gmbh	Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de)	2002-12-12	2006-02-09	Sanofi-Aventis Deutschland Gmbh	Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
JP4679155B2 (ja)	2002-12-25	2011-04-27	キッセイ薬品工業株式会社	含窒素複素環誘導体、それを含有する医薬組成物およびその医薬用途
AU2003299966A1 (en)	2003-01-03	2004-08-10	Bristol-Myers Squibb Company	Methods of producing c-aryl glucoside sglt2 inhibitors
CN1802366B (zh)	2003-03-14	2010-12-22	安斯泰来制药有限公司	C-糖苷衍生物及其盐
US7439232B2 (en)	2003-04-01	2008-10-21	Taisho Pharmaceutical Co., Ltd.	Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
EP1609799A4 (en)	2003-04-01	2008-10-29	Taisho Pharmaceutical Co Ltd	HETEROARYL-5-THIO-BETA-D-GLUCOPYRANOSIDE DERIVATIVES AND AGENTS AGAINST DIABETES THEREOF
UA86042C2 (en)	2003-08-01	2009-03-25	Янссен Фармацевтика Н.В.	Substituted indazole-o-glucosides
TW200524951A (en)	2003-08-01	2005-08-01	Janssen Pharmaceutica Nv	Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
AU2004261660A1 (en)	2003-08-01	2005-02-10	Janssen Pharmaceutica N.V.	Substituted fused heterocyclic C-glycosides
EP1680131A4 (en)	2003-08-01	2009-05-27	Janssen Pharmaceutica Nv	SUBSTITUTED INDOLE-O-GLUCOSIDES
RS20060320A (sr)	2003-08-01	2008-08-07	Janssen Pharmaceutica N.V.,	Supstituisani indazol-o-glukozidi
US7375090B2 (en)	2003-08-26	2008-05-20	Boehringer Ingelheim International Gmbh	Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
WO2005021566A2 (de)	2003-08-26	2005-03-10	Boehringer Ingelheim International Gmbh	Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2005034878A2 (en)	2003-10-08	2005-04-21	President And Fellows Of Harvard College	Pyrovalerone analogs and therapeutic uses thereof
US7371732B2 (en)	2003-12-22	2008-05-13	Boehringer Ingelheim International Gmbh	Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
DE102004017793A1 (de)	2004-02-21	2005-09-08	Biofrontera Discovery Gmbh	Trioxacarcine und deren Verwendung
US20050197270A1 (en)	2004-02-24	2005-09-08	Novozymes A/S	Enzyme stabilization in liquid detergents
RU2387663C2 (ru)	2004-03-04	2010-04-27	Киссеи Фармасьютикал Ко., Лтд.	Конденсированные гетероциклические производные, содержащие их медицинские композиции и их медицинское применение
EP2360165A3 (de)	2004-03-16	2012-01-04	Boehringer Ingelheim International GmbH	Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2006002233A2 (en)	2004-06-22	2006-01-05	Wall, Michael, A.	Alvaradoins e-n, new antitumor and cytotoxic anthracenone g-glycosides
US7393836B2 (en)	2004-07-06	2008-07-01	Boehringer Ingelheim International Gmbh	D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
US20070293690A1 (en)	2004-07-08	2007-12-20	Hiroshi Tomiyama	Process for Production of Azulene Derivatives and Intermediates for the Synthesis of the Same
EP1930313A3 (en)	2004-07-08	2008-11-19	Ciba Holding Inc.	Preparation of alpha-aminoketones
DE102004034690A1 (de)	2004-07-17	2006-02-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1782828B1 (en)	2004-07-21	2016-06-29	Kissei Pharmaceutical Co., Ltd.	Progression inhibitor for disease attributed to abnormal accumulation of liver fat
TW200606129A (en)	2004-07-26	2006-02-16	Chugai Pharmaceutical Co Ltd	Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
EP1773800A1 (de)	2004-07-27	2007-04-18	Boehringer Ingelheim International GmbH	D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE102004046583A1 (de)	2004-09-23	2006-03-30	Boehringer Ingelheim Pharma Gmbh & Co. Kg	D-Xylopyranosyl-phenyl-substituierte Cyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2006018150A1 (de) *	2004-08-11	2006-02-23	Boehringer Ingelheim International Gmbh	D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE102004039096A1 (de) *	2004-08-11	2006-02-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	D-Xylopyranosyl-phenyl-substituierte Cyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE102004048388A1 (de)	2004-10-01	2006-04-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1809381A2 (en)	2004-10-06	2007-07-25	Recepticon ApS	Use of compounds for the prevention of drug-induced cell toxicity
AU2005301957B2 (en)	2004-11-03	2012-02-23	Department Of Health And Human Services	Novobiocin analogues as anticancer agents
US7622451B2 (en)	2004-11-03	2009-11-24	University Of Kansas	Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
TW200637839A (en)	2005-01-07	2006-11-01	Taisho Pharmaceutical Co Ltd	1-thio-d-glucitol derivatives
WO2006089872A1 (en)	2005-02-23	2006-08-31	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted ( (hetero)arylethynyl-benzyd-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
AU2006229975A1 (en)	2005-03-25	2006-10-05	Inspire Pharmaceuticals, Inc.	Cytoskeletal active compounds, composition and use
US20060240496A1 (en)	2005-04-21	2006-10-26	Lakshmi Anne	Immunogens, derivatives and immunoassay for ethyl glucuronide
US7723309B2 (en)	2005-05-03	2010-05-25	Boehringer Ingelheim International Gmbh	Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
ATE484499T1 (de)	2005-08-30	2010-10-15	Boehringer Ingelheim Int	Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
US8253752B2 (en)	2006-07-20	2012-08-28	Qualcomm Incorporated	Method and apparatus for encoder assisted pre-processing
JP5452223B2 (ja)	2006-07-24	2014-03-26	テトラロジックファーマシューティカルズコーポレーション	Ｉａｐ阻害剤
TWI499414B (zh)	2006-09-29	2015-09-11	Lexicon Pharmaceuticals Inc	鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ２）的抑制物與其應用方法
US20080107744A1 (en) *	2006-11-06	2008-05-08	Jack Fa-De Chu	Injectable hollow tissue filler
US7846945B2 (en)	2007-03-08	2010-12-07	Lexicon Pharmaceuticals, Inc.	Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
ES2375800T3 (es)	2007-07-26	2012-03-06	Lexicon Pharmaceuticals, Inc.	Métodos y compuestos útiles para la preparación de inhibidores de cotransportador 2 de sódio-glucosa.
US8015005B2 (en)	2008-02-15	2011-09-06	Motorola Mobility, Inc.	Method and apparatus for voice searching for stored content using uniterm discovery
TWI472521B (zh)	2008-07-17	2015-02-11	Lexicon Pharmaceuticals Inc	（２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
EP2925735B1 (en) *	2012-11-20	2019-03-13	Lexicon Pharmaceuticals, Inc.	Inhibitors of sodium glucose cotransporter 1

2007
- 2007-09-19 TW TW096134994A patent/TWI499414B/zh active
- 2007-09-27 PT PT07843301T patent/PT2089361E/pt unknown
- 2007-09-27 NZ NZ575811A patent/NZ575811A/en unknown
- 2007-09-27 AU AU2007304971A patent/AU2007304971B2/en active Active
- 2007-09-27 DK DK10194063.3T patent/DK2308841T3/da active
- 2007-09-27 MX MX2009003305A patent/MX2009003305A/es active IP Right Grant
- 2007-09-27 EP EP10194063.3A patent/EP2308841B1/en active Active
- 2007-09-27 US US11/862,690 patent/US7781577B2/en active Active
- 2007-09-27 KR KR1020097008685A patent/KR101492277B1/ko active Active
- 2007-09-27 EP EP07843301A patent/EP2089361B1/en active Active
- 2007-09-27 CA CA2664688A patent/CA2664688C/en active Active
- 2007-09-27 PT PT101940633T patent/PT2308841E/pt unknown
- 2007-09-27 KR KR1020147033635A patent/KR20150002889A/ko not_active Withdrawn
- 2007-09-27 ES ES10194063.3T patent/ES2477216T3/es active Active
- 2007-09-27 EA EA200970337A patent/EA016511B1/ru not_active IP Right Cessation
- 2007-09-27 JP JP2009530593A patent/JP5283625B2/ja active Active
- 2007-09-27 DE DE602007012292T patent/DE602007012292D1/de active Active
- 2007-09-27 AT AT07843301T patent/ATE496888T1/de active
- 2007-09-27 DK DK07843301.8T patent/DK2089361T5/da active
- 2007-09-27 PL PL07843301T patent/PL2089361T4/pl unknown
- 2007-09-27 WO PCT/US2007/079654 patent/WO2008042688A2/en not_active Ceased
- 2007-09-27 BR BRPI0717156A patent/BRPI0717156B8/pt active IP Right Grant
- 2007-09-27 PL PL10194063T patent/PL2308841T3/pl unknown
- 2007-09-28 AR ARP070104306A patent/AR063047A1/es active IP Right Grant
2009
- 2009-03-26 IL IL197836A patent/IL197836A/en active IP Right Grant
- 2009-04-28 NO NO20091700A patent/NO345139B1/no unknown
2010
- 2010-08-18 US US12/858,666 patent/US8476413B2/en active Active
2012
- 2012-11-20 JP JP2012254023A patent/JP5701845B2/ja active Active
2013
- 2013-06-25 US US13/925,981 patent/US9365602B2/en active Active
2015
- 2015-02-17 JP JP2015028510A patent/JP5889453B2/ja active Active
2016
- 2016-05-16 US US15/155,780 patent/US20170087172A1/en not_active Abandoned
2018
- 2018-03-27 US US15/937,496 patent/US20190099436A1/en not_active Abandoned
2019
- 2019-08-15 HU HUS1900038C patent/HUS1900038I1/hu unknown
- 2019-08-30 NL NL301003C patent/NL301003I2/nl unknown
- 2019-09-19 FR FR19C1053C patent/FR19C1053I2/fr active Active

Also Published As

Publication number	Publication date
EP2089361A2 (en)	2009-08-19
BRPI0717156B8 (pt)	2021-05-25
AU2007304971A1 (en)	2008-04-10
BRPI0717156B1 (pt)	2020-06-30
KR101492277B1 (ko)	2015-02-11
MX2009003305A (es)	2009-05-28
DK2308841T3 (da)	2014-06-30
US8476413B2 (en)	2013-07-02
EP2089361B1 (en)	2011-01-26
AR063047A1 (es)	2008-12-23
NL301003I2 (nl)	2019-10-29
WO2008042688A3 (en)	2008-06-12
JP2013079243A (ja)	2013-05-02
ES2477216T3 (es)	2014-07-16
US20170087172A1 (en)	2017-03-30
NO345139B1 (no)	2020-10-12
EA016511B1 (ru)	2012-05-30
JP5701845B2 (ja)	2015-04-15
JP2015120736A (ja)	2015-07-02
KR20090061072A (ko)	2009-06-15
US20140135277A1 (en)	2014-05-15
JP2010504998A (ja)	2010-02-18
DK2089361T5 (da)	2012-01-16
TWI499414B (zh)	2015-09-11
AU2007304971B2 (en)	2013-06-20
CA2664688A1 (en)	2008-04-10
WO2008042688A2 (en)	2008-04-10
US20190099436A1 (en)	2019-04-04
PL2089361T4 (pl)	2012-09-28
EP2308841A2 (en)	2011-04-13
FR19C1053I1 (fr)	2019-11-15
ATE496888T1 (de)	2011-02-15
NZ575811A (en)	2011-10-28
PL2308841T3 (pl)	2014-09-30
IL197836A0 (en)	2009-12-24
EA200970337A1 (ru)	2009-08-28
IL197836A (en)	2014-01-30
JP5283625B2 (ja)	2013-09-04
PL2089361T3 (pl)	2011-06-30
PT2089361E (pt)	2011-05-02
JP5889453B2 (ja)	2016-03-22
KR20150002889A (ko)	2015-01-07
US7781577B2 (en)	2010-08-24
TW200826929A (en)	2008-07-01
NL301003I1 (da)	2019-09-02
EP2308841B1 (en)	2014-04-16
HUS1900038I1 (hu)	2019-09-30
DE602007012292D1 (de)	2011-03-10
US9365602B2 (en)	2016-06-14
EP2308841A3 (en)	2011-10-26
PT2308841E (pt)	2014-06-11
BRPI0717156A2 (pt)	2013-10-15
US20100311673A1 (en)	2010-12-09
FR19C1053I2 (fr)	2020-04-03
US20080113922A1 (en)	2008-05-15
CA2664688C (en)	2015-03-17
NO20091700L (no)	2009-06-16

Publication	Publication Date	Title
DK2089361T5 (da)	2012-01-16	Inhibitorer af natriumglucose-cotransportør 2 og fremgangsmåder til deres anvendelse
DK2183263T3 (da)	2012-01-30	Fremgangsmåder og forbindelser anvendelige til fremstilling af natriumglucose-cotransportør-2-inhibitorer
NO20091423L (no)	2009-06-10	Pyrimidinderivater og deres anvendelse som kinaseinhibitorer
DK3438131T3 (da)	2022-04-11	Oligosaccharidmodifikation og mærkning af proteiner
DK1791852T3 (da)	2009-04-06	C-aryl glucosid -SGLT2-inhibitorer og metode til deres fremstilling
CY2014012I2 (el)	2015-12-09	Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DK2099447T3 (da)	2013-02-18	Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
DK1940839T3 (da)	2013-10-14	Pyridopyrimidione Inhibitors of P13Ka
DK2041129T3 (da)	2014-10-13	Inhibitorer af human proteintyrosinphosphatase og deres farmaceutiske anvendelse
DK1979326T3 (da)	2013-01-07	Pyridin- og pyrimidinderivater som inhibitorer af histondeacetylase
DK2049557T3 (da)	2011-06-14	1-(-D-glycopyranosyl)-3-(4-cyclopropylphenylmethyl)-4-halogenindolderivater og anvendelse heraf som sglt-inhibitorer
DK2121614T3 (da)	2012-09-17	Aminonikotin og isonikotinsyrederivater som dhodh-inhibitorer
DK1922307T3 (da)	2012-04-02	Heterocykliske inhibitorer af MEK og fremgangsmåder til anvendelse heraf
NO20084764L (no)	2009-01-06	Tioksantinderivater og deres anvendelse som MPO inhibitorer
DK1989206T3 (da)	2012-10-08	E1-aktiveringsenzymhæmmere
DK2578685T3 (da)	2019-06-03	Rna indeholende modificerede nukleosider og fremgangsmåder til anvendelse deraf
DK2332909T3 (da)	2014-11-10	Hydroxybenzamidderivater og deres anvendelse som inhibitorer af hsp90
DK1931645T3 (da)	2014-09-29	N-(3-aminoquinoxalin-2-yl)-sulfonamidderivater og deres anvendelse som inhibitorer af phosphatidylinositol-3-kinase
DK1805312T3 (da)	2009-10-19	Fremgangsmåder og midler til fremstilling af hyaluronan
DK2439205T3 (da)	2015-06-22	Carboxamidforbindelser og deres anvendelse som calpaininhibitorer
EP2016056A4 (en)	2010-11-10	IONIC VISCOELASTIC AND VISCOELASTIC SALTS
DK2229360T3 (da)	2020-09-28	Indolinonderivater og fremgangsmåde til deres fremstilling
DK2069467T3 (da)	2014-10-20	Adskillende sammensætninger og fremgangsmåder til anvendelse
DK1590360T3 (da)	2012-08-27	Fremgangsmåde til fremstilling af inhibitorer af nukleosidphosphorylaser og nukleosidaser
DK1999403T3 (da)	2014-06-16	Multikoblingssystem og fremgangsmåde relateret dertil